Cozen O’Connor: 3 Trial Losses Won't Doom Xarelto Patients

3 Trial Losses Won't Doom Xarelto Patients

Wednesday, August 23, 2017

James Heller, chair of Cozen O'Connor's Products Liability Practice Group, was quoted in Law360's article, "3 Trial Losses Won't Doom Xarelto Patients." After a hat trick of defense wins for Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals in bellwether trials over blood thinner Xarelto, consumers face an uphill task of turning the tide in their favor. Consumers have been unable to convince jurors that Bayer and Janssen didn’t adequately instruct their treating physicians about the risks of dangerous internal bleeding associated with the blood thinner. James told Law360, "They have to find a case where the doctor is not going to strongly support the defendant. That’s what they need to stop the momentum in this litigation.”

To read the full article, click here